Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript

Operator

Good afternoon, and welcome to the Equillium Bio Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Equillium website following the conclusion of the event.

I’d now like to turn the call over to your host, Bruce Steel, Chief Executive Officer at Equillium Bio. Please go ahead, Bruce.

Bruce Steel
Co-Founder, CEO & Director

Thank you very much. Good morning and/or good afternoon to everybody for joining today. We greatly appreciate you taking your time to learn more about the aryl hydrocarbon receptor and our EQ504 program. We will, during the course of the day at the company side, be making potentially some forward-looking statements, so we refer you to our disclaimer here.

We are very pleased today to have Dr. Francisco Quintana and Dr. Brian Feagan, who are experts in their fields covering immune-mediated disorders and gastroenterology, respectively. We will be discussing an overview of the aryl hydrocarbon receptor and why this is such a compelling drug target across a range of potential immune-mediated diseases. Obviously, our focus as a company with EQ504 will be directing this program initially into the treatment of ulcerative colitis, where despite an enormous amount of investment in many approved drugs across different modalities, there remains a very high unmet medical